Leveraging Multi-Omic Testing to Advance RAS-Targeted Cancer Therapies
Time: 10:15 am
day: Day Two
Details:
- Innovations in RAS Mutation Detection and Personalized Treatment: ddPCR™ testing enhances the detection of RAS mutations, facilitating earlier diagnosis, personalized therapy development, and longitudinal monitoring of disease recurrence in RAS-mutant cancers.
- Integrating Proteomics for Comprehensive RAS Targeting: Proteomic testing identifies a patients' immune response to RAS mutant positive cancers, enabling the identification of aggressive cancer phenotypes and informing combination strategies, such as enhanced surveillance, immunotherapy, and chemotherapy for improved patient outcomes.
(Biodesix, Biodesix logo are registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.)
